{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:29:07Z","timestamp":1772119747007,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s11060-013-1048-z","type":"journal-article","created":{"date-parts":[[2013,1,8]],"date-time":"2013-01-08T11:42:50Z","timestamp":1357645370000},"page":"209-215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["\u201cOne week on\u2013one week off\u201d: efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center"],"prefix":"10.1007","volume":"112","author":[{"given":"Norbert","family":"Galldiks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Berhorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Blau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Dunkl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gereon R.","family":"Fink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Schroeter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,1]]},"reference":[{"key":"1048_CR1","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3747\/co.v18i3.755","volume":"18","author":"JC Easaw","year":"2011","unstructured":"Easaw JC, Mason WP, Perry J, Laperriere N, Eisenstat DD, Del Maestro R, Belanger K, Fulton D, Macdonald D (2011) Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol 18:126\u2013136","journal-title":"Curr Oncol"},{"key":"1048_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996","journal-title":"N Engl J Med"},{"key":"1048_CR3","doi-asserted-by":"publisher","first-page":"5874","DOI":"10.1200\/JCO.2009.23.6497","volume":"27","author":"W Wick","year":"2009","unstructured":"Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874\u20135880","journal-title":"J Clin Oncol"},{"key":"1048_CR4","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1002\/cncr.25256","volume":"116","author":"MC Chamberlain","year":"2010","unstructured":"Chamberlain MC (2010) Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer 116:3988\u20133999","journal-title":"Cancer"},{"key":"1048_CR5","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1002\/cncr.26381","volume":"118","author":"A Desjardins","year":"2012","unstructured":"Desjardins A, Reardon DA, Coan A, Marcello J, Herndon JE 2nd, Bailey L, Peters KB, Friedman HS, Vredenburgh JJ (2012) Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 118:1302\u20131312","journal-title":"Cancer"},{"key":"1048_CR6","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s00415-009-5006-9","volume":"256","author":"A Wick","year":"2009","unstructured":"Wick A, Pascher C, Wick W, Jauch T, Weller M, Bogdahn U, Hau P (2009) Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol 256:734\u2013741","journal-title":"J Neurol"},{"key":"1048_CR7","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1212\/01.WNL.0000127617.89363.84","volume":"62","author":"W Wick","year":"2004","unstructured":"Wick W, Steinbach JP, Kuker WM, Dichgans J, Bamberg M, Weller M (2004) One week on\/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 62:2113\u20132115","journal-title":"Neurology"},{"key":"1048_CR8","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1200\/JCO.2007.10.7722","volume":"25","author":"A Wick","year":"2007","unstructured":"Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, Meyermann R, Reifenberger G, Weller M, Wick W (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25:3357\u20133361","journal-title":"J Clin Oncol"},{"key":"1048_CR9","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1200\/JCO.2004.00.8417","volume":"23","author":"W Wick","year":"2005","unstructured":"Wick W, Weller M (2005) How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. J Clin Oncol 23:4235\u20134236","journal-title":"J Clin Oncol"},{"key":"1048_CR10","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/sj.bjc.6603376","volume":"95","author":"AA Brandes","year":"2006","unstructured":"Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, Biscuola M, Blatt V, Crino L, Ermani M (2006) Temozolomide 3\u00a0weeks on and 1\u00a0week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 95:1155\u20131160","journal-title":"Br J Cancer"},{"key":"1048_CR11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s11060-010-0423-2","volume":"103","author":"U Abacioglu","year":"2011","unstructured":"Abacioglu U, Caglar HB, Yumuk PF, Akgun Z, Atasoy BM, Sengoz M (2011) Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma. J Neurooncol 103:585\u2013593","journal-title":"J Neurooncol"},{"key":"1048_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/07357900701708393","volume":"26","author":"B Neyns","year":"2008","unstructured":"Neyns B, Chaskis C, Joosens E, Menten J, D\u2019Hondt L, Branle F, Sadones J, Michotte A (2008) A multicenter cohort study of dose-dense temozolomide (21 of 28\u00a0days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. Cancer Investig 26:269\u2013277","journal-title":"Cancer Investig"},{"key":"1048_CR13","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1200\/JCO.2009.26.5520","volume":"28","author":"JR Perry","year":"2010","unstructured":"Perry JR, Belanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF (2010) Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28:2051\u20132057","journal-title":"J Clin Oncol"},{"key":"1048_CR14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/neuonc\/nop030","volume":"12","author":"DS Kong","year":"2010","unstructured":"Kong DS, Lee JI, Kim JH, Kim ST, Kim WS, Suh YL, Dong SM, Nam DH (2010) Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol 12:289\u2013296","journal-title":"Neuro Oncol"},{"key":"1048_CR15","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997\u20131003","journal-title":"N Engl J Med"},{"key":"1048_CR16","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1056\/NEJM200011093431901","volume":"343","author":"M Esteller","year":"2000","unstructured":"Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350\u20131354","journal-title":"N Engl J Med"},{"key":"1048_CR17","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1093\/brain\/awm204","volume":"130","author":"D Krex","year":"2007","unstructured":"Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G, Weller M, Schackert G (2007) Long-term survival with glioblastoma multiforme. Brain 130:2596\u20132606","journal-title":"Brain"},{"key":"1048_CR18","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/sj.bjc.6600827","volume":"88","author":"AW Tolcher","year":"2003","unstructured":"Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, Goetz AD, Schwartz G, Edwards T, Reyderman L, Statkevich P, Cutler DL, Rowinsky EK (2003) Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88:1004\u20131011","journal-title":"Br J Cancer"},{"key":"1048_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11060-012-0878-4","volume":"109","author":"D Beier","year":"2012","unstructured":"Beier D, Schriefer B, Brawanski K, Hau P, Weis J, Schulz JB, Beier CP (2012) Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines. J Neurooncol 109:45\u201352","journal-title":"J Neurooncol"},{"key":"1048_CR20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s11060-012-0832-5","volume":"108","author":"W Taal","year":"2012","unstructured":"Taal W, Segers-van Rijn JM, Kros JM, van Heuvel I, van der Rijt CC, Bromberg JE, Sillevis Smitt PA, van den Bent MJ (2012) Dose dense 1\u00a0week on\/1\u00a0week off temozolomide in recurrent glioma: a retrospective study. J Neurooncol 108:195\u2013200","journal-title":"J Neurooncol"},{"key":"1048_CR21","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","volume":"8","author":"DR Macdonald","year":"1990","unstructured":"Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277\u20131280","journal-title":"J Clin Oncol"},{"key":"1048_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000065718","volume":"63","author":"AA Brandes","year":"2002","unstructured":"Brandes AA, Ermani M, Basso U, Paris MK, Lumachi F, Berti F, Amista P, Gardiman M, Iuzzolino P, Turazzi S, Monfardini S (2002) Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study. Oncology 63:38\u201341","journal-title":"Oncology"},{"key":"1048_CR23","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1023\/A:1008382516636","volume":"12","author":"M Brada","year":"2001","unstructured":"Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, Zaknoen S (2001) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12:259\u2013266","journal-title":"Ann Oncol"},{"key":"1048_CR24","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1054\/bjoc.2000.1316","volume":"83","author":"WK Yung","year":"2000","unstructured":"Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA (2000) A phase II study of temozolomide versus procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588\u2013593","journal-title":"Br J Cancer"},{"key":"1048_CR25","doi-asserted-by":"publisher","first-page":"4601","DOI":"10.1200\/JCO.2009.27.1932","volume":"28","author":"M Brada","year":"2010","unstructured":"Brada M, Stenning S, Gabe R, Thompson LC, Levy D, Rampling R, Erridge S, Saran F, Gattamaneni R, Hopkins K, Beall S, Collins VP, Lee SM (2010) Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol 28:4601\u20134608","journal-title":"J Clin Oncol"},{"key":"1048_CR26","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/bjc.1993.42","volume":"67","author":"SM Lee","year":"1993","unstructured":"Lee SM, Thatcher N, Dougal M, Margison GP (1993) Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells. Br J Cancer 67:216\u2013221","journal-title":"Br J Cancer"},{"key":"1048_CR27","doi-asserted-by":"crossref","unstructured":"Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi M, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge SC, Brown PD, Chakravarti A, Curran WJ, Mehta MP: RTOG 0525: a randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). J Clin Oncol 29: (suppl; abstr 2006), 2011","DOI":"10.1200\/jco.2011.29.15_suppl.2006"},{"key":"1048_CR28","first-page":"2933","volume":"57","author":"HS Friedman","year":"1997","unstructured":"Friedman HS, Johnson SP, Dong Q, Schold SC, Rasheed BK, Bigner SH, Ali-Osman F, Dolan E, Colvin OM, Houghton P, Germain G, Drummond JT, Keir S, Marcelli S, Bigner DD, Modrich P (1997) Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res 57:2933\u20132936","journal-title":"Cancer Res"},{"key":"1048_CR29","doi-asserted-by":"publisher","first-page":"4859","DOI":"10.1158\/1078-0432.CCR-07-4807","volume":"14","author":"JA Maxwell","year":"2008","unstructured":"Maxwell JA, Johnson SP, McLendon RE, Lister DW, Horne KS, Rasheed A, Quinn JA, Ali-Osman F, Friedman AH, Modrich PL, Bigner DD, Friedman HS (2008) Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clin Cancer Res 14:4859\u20134868","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-013-1048-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-013-1048-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-013-1048-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-013-1048-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T22:12:54Z","timestamp":1598911974000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-013-1048-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["1048"],"URL":"https:\/\/doi.org\/10.1007\/s11060-013-1048-z","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717972232.793469663","asserted-by":"object"}]},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"31 August 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}